Lena Claesson-Welsh

Prof. Lena Claesson-Welsh


Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
AOAnna-Karin Olsson
Anna-Karin Olsson
ADAnna Dimberg
Anna Dimberg
JKJohan Kreuger
Johan Kreuger
LCLena Claesson-Welsh
Lena Claesson-Welsh

19 January 2013 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
LCLena Claesson-Welsh
Lena Claesson-Welsh
Michael WelshMichael Welsh
Michael Welsh

1 April 2001 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
MCMichael J Cross
Michael J Cross
LCLena Claesson-Welsh
Lena Claesson-Welsh

6 March 2012 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Closed access
PDF file
SKSina Koch
Sina Koch
LCLena Claesson-Welsh
Lena Claesson-Welsh
Vascular endothelial growth factors (VEGFs) are master regulators of vascular development and of blood and lymphatic vessel function during health and disease in the adult. It is therefore important to understand the mechanism of action of this family of five mammalian ligands, which act through three receptor tyrosine kinases (RTKs). In addition, coreceptors like neuropilins (NRPs) and integrins associate with the ligand/receptor signaling complex and modulate the output. Therapeutics to block several of the VEGF signaling components have been developed with the aim to halt blood vessel formation, angiogenesis, in diseases that involve tissue growth and inflammation, such as cancer. In this review, we outline the current information on VEGF signal transduction in relation to blood and lymphatic vessel biology.

28 June 2011 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
SKSina Koch
Sina Koch
STSònia Tugues
Sònia Tugues
XLXiujuan Li
Xiujuan Li
LGLaura Gualandi
Laura Gualandi
LCLena Claesson-Welsh
Lena Claesson-Welsh
VEGFs (vascular endothelial growth factors) control vascular development during embryogenesis and the function of blood vessels and lymphatic vessels in the adult. There are five related mammalian ligands, which act through three receptor tyrosine kinases. Signalling is modulated through neuropilins, which act as VEGF co-receptors. Heparan sulfate and integrins are also important modulators of VEGF signalling. Therapeutic agents that interfere with VEGF signalling have been developed with the aim of decreasing angiogenesis in diseases that involve tissue growth and inflammation, such as cancer. The present review will outline the current understanding and consequent biology of VEGF receptor signalling.

1 April 2021 in Trends in Molecular Medicine
Verified
Journal Article
Open access
LCLena Claesson-Welsh
Lena Claesson-Welsh
EDElisabetta Dejana
Elisabetta Dejana
DMDonald M. McDonald
Donald M. McDonald
Leakage from blood vessels into tissues is governed by mechanisms that control endothelial barrier function to maintain homeostasis. Dysregulated endothelial permeability contributes to many conditions and can influence disease morbidity and treatment. Diverse approaches used to study endothelial permeability have yielded a wealth of valuable insights. Yet, ongoing questions, technical challenges, and unresolved controversies relating to the mechanisms and relative contributions of barrier regulation, transendothelial sieving, and transport of fluid, solutes, and particulates complicate interpretations in the context of vascular physiology and pathophysiology. Here, we describe recent in vivo findings and other advances in understanding endothelial barrier function with the goal of identifying and reconciling controversies over cellular and molecular processes that regulate the vascular barrier in health and disease.